22nd Oct 2025 10:22
(Alliance News) - GSK PLC and Nasdaq-listed Alector Inc on Wednesday said they won't proceed with a study into a possible dementia treatment after trial results failed to meet hopes.
The Infront-3 trial was evaluating latozinemab in individuals with frontotemporal dementia due to a mutation in the progranulin gene, FTD-GRN.
In a statement, London-based pharmaceuticals firm GSK, and San Francisco-based Alector said although latozinemab treatment resulted in a statistically significant effect on the Infront-3 biomarker co-primary endpoint of plasma progranulin concentrations, it did not show benefit on the clinical co-primary endpoint of slowing FTD-GRN progression.
The secondary and exploratory endpoints also did not demonstrate treatment-related effects on FTD-GRN, the firms added.
"Based on these results, the open-label extension portion of the Infront-3 trial and the continuation study for latozinemab will be discontinued," the statement continued.
Shares in GSK were down 0.2% at 1,642.50 pence each in London on Wednesday morning, while Alector plunged 58% in pre-market trading in New York.
Late Tuesday, Alector said it will cut 49% of its workforce, while Head of Research and Development Sara Kenkare-Mitra has resigned.
In July 2021, GSK and Alector entered into a collaboration and license agreement to collaborate on the global development and commercialisation of progranulin-elevating monoclonal antibodies, including latozinemab.
Alector led the global clinical development of latozinemab through phase 2 proof-of-concept.
Thereafter, Alector and GSK shared development responsibilities and all costs for global development were divided between the two companies.
In addition, GSK announced positive phase III data from its clinical programme to develop a next-generation version of its metered dose inhaler, salbutamol.
The data confirmed therapeutic equivalence and comparable safety profile for salbutamol containing an innovative low carbon propellant.
The findings will support regulatory submissions for the next-generation version, with launch expected from 2026.
GSK said, if approved, the low carbon salbutamol has the potential to reduce greenhouse gas emissions by 92% per inhaler.
By Jeremy Cutler, Alliance News reporter
Comments and questions to [email protected]
Copyright 2025 Alliance News Ltd. All Rights Reserved.
Related Shares:
Glaxosmithkline